Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$206.58 USD
-0.77 (-0.37%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $206.64 +0.06 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRL 206.58 -0.77(-0.37%)
Will CRL be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
Charles River (CRL) Inks CDMO Deal With Gates Institutes
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
Charles River (CRL) Partners to Reduce Animal Research Usage
Charles River (CRL) Launches Viral Vector Tech Transfer Program
Other News for CRL
Charles River Labs downgraded at Argus on cautious biotech spending
Nike and Alphabet downgraded: Wall Street's top analyst calls
These Nike Analysts Are No Longer Bullish; Here Are Top 5 Downgrades For Friday
Demystifying Charles River: Insights From 4 Analyst Reviews
Charles River just downgraded at Argus, here's why